Workflow
生物过滤
icon
Search documents
洁特生物: 关于“洁特转债”跟踪信用评级结果的公告
Zheng Quan Zhi Xing· 2025-06-27 16:49
Group 1 - The company's credit rating remains at A+ with a stable outlook for both the company and its convertible bonds [1][2] - The credit rating agency Zhongzheng Pengyuan conducted a follow-up credit rating for the company on June 26, 2025, confirming the ratings [2] - The previous credit rating was also A+ with a stable outlook, assessed on June 26, 2024 [1][2] Group 2 - The follow-up rating report was published on the Shanghai Stock Exchange website on the same day as the rating [2]
洁特生物: 民生证券股份有限公司关于广州洁特生物过滤股份有限公司差异化分红事项的核查意见
Zheng Quan Zhi Xing· 2025-06-24 19:25
Core Viewpoint - The company, Guangzhou Jiete Biological Filtration Co., Ltd., is implementing a differentiated dividend distribution plan for the year 2024, which is based on the number of shares available after accounting for shares repurchased and held in a special account [1][2][5]. Group 1: Reasons for Differentiated Dividend - The differentiated dividend is a result of the company's decision to repurchase shares using its own or raised funds, with a total repurchase amount between RMB 20 million and RMB 40 million, and a maximum repurchase price of RMB 19.36 per share [1][2]. - The repurchased shares will not participate in profit distribution, leading to the need for a differentiated dividend distribution plan [2][3]. Group 2: Dividend Distribution Plan - The company plans to distribute a cash dividend of RMB 0.73 per 10 shares (including tax) to all shareholders based on the total share capital minus the repurchased shares [2][3]. - The actual number of shares participating in the distribution is 137,632,306 shares, calculated from the total share capital of 140,363,220 shares after deducting the repurchased shares [3][4]. Group 3: Calculation Basis for Differentiated Dividend - The cash dividend per share is calculated based on the adjusted total share capital, and the reference price for ex-dividend trading is determined using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [3][4]. - The impact of the differentiated dividend on the ex-dividend reference price is minimal, with an absolute value change of less than 1% [4]. Group 4: Verification Opinion - The sponsoring institution, Minsheng Securities, confirms that the differentiated dividend distribution complies with relevant laws and regulations, ensuring no harm to the interests of the company and all shareholders [5][6].
洁特生物: 关于实施2024年年度权益分派时调整“洁特转债”转股价格的公告
Zheng Quan Zhi Xing· 2025-06-24 19:25
Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of the 2024 annual profit distribution plan, which includes a cash dividend of 0.73 yuan per 10 shares [1][2][4]. Summary by Sections Announcement of Adjustment - The conversion price of "洁特转债" will be adjusted from 48.02 yuan per share to 47.95 yuan per share, effective from July 2, 2025 [1][4]. - The trading of "洁特转债" will be suspended from June 24, 2025, until the equity registration date of July 1, 2025, and will resume on July 2, 2025 [1][4]. Basis for Adjustment - The adjustment is based on the resolution passed at the 2024 annual general meeting, which approved a cash dividend distribution of 0.73 yuan per 10 shares, with no stock increases or bonus shares [1][2][4]. - The total number of shares after excluding repurchased shares is 140,363,220, with 2,730,914 shares repurchased [4]. Calculation of Adjustment - The cash dividend per share is calculated as approximately 0.0716 yuan, leading to the new conversion price being calculated as follows: P1 = P0 - D, where P0 is the old conversion price and D is the cash dividend [4]. - The formula for adjusting the conversion price is provided, detailing how various corporate actions affect the conversion price [2][4]. Other Information - Investors seeking more details about "洁特转债" can refer to the company's prospectus published on June 24, 2022 [5].
洁特生物: 关于“洁特转债”2025年付息的公告
Zheng Quan Zhi Xing· 2025-06-23 12:20
Core Viewpoint - The announcement details the interest payment schedule for the company's convertible bonds, including key dates and interest rates, ensuring compliance with regulatory requirements [1][2][3]. Group 1: Convertible Bond Issuance Overview - The company issued 4.4 million convertible bonds on June 28, 2022, with a total fundraising amount of 440 million RMB [1][2]. - The bonds have a six-year term, maturing on June 27, 2028, and feature a tiered interest rate structure, starting at 0.30% in the first year and reaching 2.00% by the sixth year [1][2]. Group 2: Interest Payment Details - The third interest payment will occur on June 30, 2025, covering the period from June 28, 2024, to June 27, 2025, with a coupon rate of 1.00% [3][4]. - The interest amount payable per bond is 1.00 RMB (before tax) for each bond with a face value of 100 RMB [3][5]. Group 3: Payment Schedule and Methods - The bondholders' registration date for interest payment is June 27, 2025, with the ex-dividend date also set for June 30, 2025 [3][4]. - The company has appointed China Securities Depository and Clearing Corporation Limited Shanghai Branch to handle the interest payment process [4][6]. Group 4: Tax Implications for Investors - Individual investors are subject to a 20% tax on interest income, resulting in a net payment of 0.80 RMB per bond after tax [5]. - Non-resident investors are exempt from corporate income tax on bond interest income until December 31, 2025, under specific conditions [5].
洁特生物实控人方拟减持 2020年上市2募资共8.5亿
Zhong Guo Jing Ji Wang· 2025-06-10 06:59
Core Viewpoint - The announcement from Jiet Bio (688026.SH) regarding a share reduction plan by its shareholder, Guangzhou Luogang District Huizi Investment Management Partnership, indicates a planned reduction of up to 186,315 shares, representing no more than 0.1327% of the company's total share capital, due to the shareholder's personal funding needs [1][2]. Group 1: Shareholder Reduction Plan - The shareholder, Huizi Investment, plans to reduce its holdings through centralized bidding from July 2, 2025, to October 1, 2025 [1][2]. - The total shares held by Huizi Investment before the reduction is 1,396,950 shares, which accounts for 1.00% of the company's total share capital [2]. - The shares intended for reduction were acquired before the IPO and through capital reserve conversion [2]. Group 2: Company Background - Jiet Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 22, 2020, with an issuance of 25 million shares at a price of 16.49 yuan per share [3]. - The company raised a total of 412.25 million yuan from its initial public offering, with a net amount of 379.41 million yuan after deducting issuance costs [3][5]. - The company has conducted two fundraising activities, totaling 852.25 million yuan [5]. Group 3: Financial Information - The company issued convertible bonds approved by the China Securities Regulatory Commission, raising a total of 440 million yuan, with a net amount of approximately 432.49 million yuan after expenses [4]. - The company distributed cash dividends of 0.6 yuan per share and increased its capital stock by 0.4 shares per share based on a total share capital of 100 million shares prior to the distribution [6].
广州洁特生物过滤股份有限公司股东减持股份计划公告
Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd., indicating a planned sale of shares due to personal financial needs, while ensuring that this action will not affect the company's control or governance structure [2][3][7]. Group 1: Shareholder Information - The shareholder, Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership), holds 1,396,950 shares, representing 1.00% of the company's total equity [2]. - The shares were acquired prior to the company's IPO and became tradable on January 30, 2023, after the lifting of restrictions [2]. Group 2: Reduction Plan Details - The shareholder plans to reduce their holdings by up to 186,315 shares, which is approximately 0.1327% of the total equity, within a three-month period starting from July 2, 2025, to October 1, 2025 [3]. - The reduction will be executed through centralized bidding, and any changes in the company's share structure during this period will lead to adjustments in the reduction plan [3]. Group 3: Control and Governance Impact - The reduction plan will not lead to a change in the company's control, as the shareholder is an associated party of the controlling shareholder, ensuring that governance and operational continuity remain unaffected [3][7]. - The actual controller's family member, Wang Jing, will not reduce her indirect holdings through the investment partnership, further stabilizing the control structure [3][7]. Group 4: Previous Commitments - The shareholder has previously committed not to transfer or manage shares held prior to the IPO for a period of 12 months post-listing, which aligns with the current reduction plan [5][6]. - Wang Jing has also made commitments regarding the management of her shares, including restrictions on transfer during specific periods [6].
广州洁特生物过滤股份有限公司第四届董事会第十七次会议决议公告
Core Viewpoint - The company decided not to lower the conversion price of its convertible bonds, "洁特转债," despite triggering the downward adjustment clause due to stock price fluctuations [5][9][10]. Group 1: Board Meeting Decisions - The fourth board meeting was held on April 11, 2025, where all seven participating directors unanimously agreed not to lower the conversion price of "洁特转债" [1][9]. - The decision was made considering the company's long-term development and investor interests, amidst significant stock price volatility influenced by macroeconomic and industry changes [9][10]. Group 2: Conversion Price Adjustment Details - The initial conversion price for "洁特转债" was set at 48.23 yuan per share, adjusted to 48.09 yuan on June 6, 2023, and further to 48.02 yuan on July 4, 2024, due to corporate actions [6][7]. - The downward adjustment clause was triggered as the stock price fell below 40.82 yuan (85% of the conversion price) for at least 15 out of 30 consecutive trading days [8][9]. Group 3: Future Considerations - The company will not propose a downward adjustment for the next three months (until July 11, 2025), but will reassess the situation after this period if the clause is triggered again [2][10]. - The board will convene again to decide on any future adjustments post-July 12, 2025, if necessary [2][10].